Bone Biologics Corp reports results for the quarter ended September 30 - Earnings Summary

Bone Biologics

15/11/2024 14:03

* Bone Biologics Corp  BBLG.OQ  reported a quarterly
adjusted loss
of $2.37​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of $-4.88.  The lone analyst forecast for the quarter was for a
loss of 60 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Bone Biologics Corp's reported EPS for the quarter was a
loss of
$2.37​.
    * The company reported a quarterly loss of $4.15 million.
    * Bone Biologics Corp shares had fallen by 39.4% this
quarter and
lost 71.5% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * 
    * Wall Street's median 12-month price target for Bone
Biologics
Corp is 16.75 

This summary was machine generated from LSEG data November 15 at
02:03 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.60          -2.37          Missed
 Jun. 30 2024      -1.39          -0.67          Beat
 Mar. 31 2024      -7.60          -1.31          Beat
 Dec. 31 2023      -5.60          -2.47          Beat